Skip Navigation

People
Events
News

LinkedIn
Twitter
Instagram
Facebook
YouTube
Email

People
Events
News

Search site:

National Cancer Institute

Research & Technology
KRAS G12C
RAS drug discovery at Frederick National Laboratory reaches lung cancer patients in a clinical trial
A first-in-human study seeks to determine the drug’s safety and tolerability and to detect potential antitumor activity.
- - Program Overview
    Retroviral Evolution Section
    Retroviral Pathogenesis Section
    Retrovirus-Cell Interaction Section
    Viral Oncology Section
    Viral Persistence Section
    Sections
    Biological Products Core
    Cellular Immunity Core
    HIV Molecular Monitoring Core
    Nonhuman Primate Research Support Core
    Quantitative Molecular Diagnostics Core
    Tissue Analysis and Retroviral Protein Chemistry Core
    Viral Evolution Core
    Cores
    AIDS and Cancer Virus Program
  - Program Overview
    Computational Structural Biology Section
    Epigenetics Section
    HLA Immunogenetics Section
    Molecular Immunology Section
    Basic Science Program
  - Program Overview
    Advanced Biomedical Computational Science
    Center for Technical Operations Support
    Bioinformatics and Computational Science
  - Program Overview
    Advanced Cryo-Electron Microscopy Technology Group
    Antibody Characterization Laboratory
    Cancer Data Science Initiatives
    CLIA Molecular Diagnostics Laboratory
    Imaging Mass Cytometry Laboratory
    Protein Expression Laboratory
    Cancer Research Technology Program
  - Program Overview
    Animal Diagnostics Laboratory
    Animal Research Technical Support
    Center for Advanced Preclinical Research
    Genome Modification Core
    Gnotobiotics Facility
    Laboratory Animal Medicine
    Molecular Histopathology Laboratory
    Mouse Modeling and Cryopreservation
    Small Animal Imaging Program
    Laboratory Animal Sciences Program
  - Program Overview
    Cancer Immunoprevention Laboratory
    Center of Excellence for Serology Development and Emergency Preparedness
    HPV and COVID-19 Serology Laboratories
    SeroNet Coordinating Center
    Vaccine, Immunity, and Cancer Directorate
  Science Areas
- Clinical Trial Support
Global image data sharing
Valuable medical and biological images languish for want of support
More countries should invest in open data resources, or an immense amount of valuable data will languish, a team of concerned scientists recommended in a Nature Methods opinion column.
Different high-risk HPV infections don’t spur cancers at the same rate
Innovation & Initiatives
BBO-10203
Drug blocking cancer-driving RAS-PI3K pathway enters clinical trials
Second drug candidate targeting RAS-related cancers developed by the RAS Initiative, BridgeBio Oncology Therapeutics and Lawrence Livermore National Laboratory.
- Initiatives
- - Center for Innovation and Strategic Partnerships
  - Patents
  Innovation
- Scientific Series
Did you know?
About 30% of all human cancers are driven by mutations of the RAS family of genes. The RAS Initiative endeavors to better understand the RAS oncogene and discover its vulnerabilities to treat RAS-related cancers.
Importance of innovationWithin FNL, innovation plays a pivotal role in delivering new and enhanced technologies that empower us to tackle essential scientific inquiries, enhance our services, and ultimately contribute to the wellbeing of patients.
Vladimir Popov, Ph.D., MBA
Investigator Resources
New Researcher Resource
SeroNet study samples available to request
Investigators can request serological samples from SARS-CoV-2 studies through the SeroNet Study Collections.
SIV/SHIV
Barcode Analysis Tool
Download files to demultiplex next-generation sequencing and determine the abundance of individually barcoded SIV/SHIV viral lineages.
Assay Cascade Characterization Program
Next deadline to apply: Sept. 2, 2025
Preclinical characterization of nanoparticles to facilitate the regulatory review of nanotechnology concepts intended as cancer therapies and diagnostics.
Register nowApr 9, 2025
Driving results through crisis and uncertainty: From Operation Warp Speed to the World
Col. Matt Clark as he covers leader and followership principles and competencies.
Did you know?
We are home to unique scientific expertise and technological capabilities available nowhere else. The Technical Services Program through the Partnership Development Office makes some of these capabilities and services readily available to the external research community at-cost to advance biomedical research around the world.
FNL Initiative
Scientific Standards Hub
Collection of scientific groups at FNL working to develop, deposit and share standards and references in biological research.
Work With Us
Register Your Interest
Become a Vendor
Potential vendors seeking to work with us must first complete a New Vendor Registration.
- Collaboration
- - Intellectual Property and Strategic Agreements
  Tech Transfer & Licensing
- Vendors & Subcontractors
Partnership Spotlight
National laboratories’ publication wins best paper award
A review authored by a team spanning LLNL and FNL has been awarded one of two recent Best Paper designations among papers published in Current Opinion in Structural Biology.
Innovation
FNL Patents
More countries should invest in open data resources, or an immense amount of valuable data will languish, a team of concerned scientists recommended in a Nature Methods opinion column.
Careers
What do you enjoy about working at the Frederick National Laboratory?I enjoy coming to work every day because of the wonderful team we have.
Chris Karlovich, Ph.D.
About FNL
Did you know?
HPV Serology Laboratory helps show single dose of HPV vaccine protects as well as multi-dose.